Amgen Submits Biologics License Application To The FDA For Erenumab

Erenumab is an Investigative Treatment Specifically Designed to Prevent Migraine Only Molecule in Late-Stage Development to Directly Target the Calcitonin Gene-Related Peptide Receptor Amgen and Novartis to Co-Commercialize Erenumab in the U.S. THOUSAND OAKS, Calif., May 18, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for erenumab to prevent migraine. Erenumab is specifically designed to prevent migraine by blocking the Calcitonin Gene-Related Peptide (CGRP) receptor. This BLA includes data from pivotal studies in patients with episodic and chronic migraine. "People...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news